Dermatomyositis clinical trials

Explore recruiting dermatomyositis clinical trials.

Recruiting dermatomyositis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Dermatomyositis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered GLPG3667 once daily for 24 weeks in adult subjects with dermatomyositis

Germany, Italy, Romania, France, Bulgaria, Croatia +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults with Dermatomyositis

Hungary, Italy, Czechia, Slovakia, Netherlands, Spain +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) – The RECLAIIM Study

Hungary, France, Italy, Spain, Germany, Belgium +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart in Adults With Dermatomyositis

Greece, Poland, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase IIa, Randomized, Parallel, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants receiving Standard of Care

Italy, Poland, Czechia, Sweden, Spain, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

Dermatomyositis trials by city

Dermatomyositis in Toronto Dermatomyositis in Vancouver Dermatomyositis in Montreal Dermatomyositis in Calgary Dermatomyositis in Edmonton Dermatomyositis in Ottawa Dermatomyositis in Winnipeg Dermatomyositis in Quebec City Dermatomyositis in Hamilton Dermatomyositis in Kitchener Dermatomyositis in London Dermatomyositis in Halifax Dermatomyositis in New York Dermatomyositis in Los Angeles Dermatomyositis in Chicago Dermatomyositis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease